Clinical Trial of a Nutritional Supplement in Adults With Bipolar Disorder
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00109577|
Recruitment Status : Terminated (Unable to recruit large enough sample; large expectancy effects but no adverse events)
First Posted : April 29, 2005
Results First Posted : September 11, 2012
Last Update Posted : September 18, 2012
|Condition or disease||Intervention/treatment||Phase|
|Bipolar Disorder||Drug: MCN36 (nutritional supplement) Drug: Placebo||Phase 2|
This RCT (randomized clinical trial) compared MCN36 to placebo in patients randomized to receive one or the other for 8 weeks. Close medical supervision was provided with weekly appointments. At the end of the 8 weeks, all participants were offered the opportunity of entering an 8-week open-label extension.
The efficacy objective of this study was to assess the efficacy of MCN36 compared with placebo in otherwise medication-free adults with bipolar disorder I and II, in improving overall symptomatology at the end of 8 weeks of therapy as assessed under randomized and fully blinded conditions
- as measured by the clinician using the Overall Bipolarity Index (OBI) (primary outcome measure).
- as measured by the clinician using the Clinical Global Impressions for Bipolar Disorder (CGI-BP) for Severity.
- as measured by self-report recorded on the Outcome Questionnaire (OQ).
- in terms of rate of response, with response defined as a reduction of 50% or more in either the depression or the mood elevation component of the OBI.
- in terms of functional states and health-related quality of life as measured by The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36).
The safety-related objective was to assess the safety of MCN36 compared with placebo in terms of
- laboratory analyses
- treatment-emergent adverse events, which will be solicited at each appointment using the Adverse Event Log.
Participants had two appointments for screening and confirming suitability for the trial. Between those two appointments, they provided a blood sample, and met with a research nurse. They also kept a 7-day food record of their food intake prior to the second appointment. If suitability was confirmed at the second visit, they entered the randomized phase.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||40 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Randomized Placebo-controlled Phase II Trial of MCN36 in Adults With Bipolar Disorder|
|Study Start Date :||April 2005|
|Actual Primary Completion Date :||March 2009|
|Actual Study Completion Date :||March 2009|
Placebo Comparator: 2
Placebo comparator, 6 placebo capsules three times a day
nutritional supplement intervention, 6 nutritional supplement capsules three times a day; the nutritional supplement is a 36-ingredient micronutrient supplement (primarily vitamins and minerals) and is referred to as MCN36, because it contains 36 nutrients.
Drug: MCN36 (nutritional supplement)
- Mood as Evaluated by the Overall Bipolarity Index (Composite of the Hamilton Depression Scale and the Young Mania Rating Scale) [ Time Frame: Baseline to 8 weeks ]Change in mood from baseline to final visit, as evaluated by the Overall Bipolarity Index (composite of the Hamilton Depression Scale and the Young Mania Rating Scale); minimum possible score is 0 and maximum possible score is 103; higher scores mean worse symptomatology
- Global Clinical Impressions [ Time Frame: Baseline to 8 weeks ]
- Outcome Questionnaire --- a Self-report Questionnaire [ Time Frame: Baseline to 8 weeks ]
- Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) [ Time Frame: Baseline to 8 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00109577
|United States, California|
|Dr Estelle Goldstein|
|San Diego, California, United States, 92116|
|University of Calgary Faculty of Medicine|
|Calgary, Alberta, Canada, T2N 4N1|
|Principal Investigator:||Bonnie J Kaplan, PhD||University of Calgary|